BCR and chronic myelogenous leukemia, BCR-ABL1 positive: The tyrosine kinase activity of ABL is inhibited by imatinib, nilotinib and dasatinib, which are used in the clinic to treat chronic myelogenous leukemia (CML) caused by the oncogenic BCR-ABL tyrosine kinase [40-43].